BET bromodomain inhibitors in leukemia

Experimental Hematology

Volumn 43, Issue 8, 2015, Pages 718-731

  Basheer, Faisal ^a,b   Huntly, Brian J P ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; AZACITIDINE; BAY 1238097; BROMODOMAIN INHIBITOR; CHAPERONE; CPI 0610; CYTARABINE; NUCLEIC ACID BINDING PROTEIN; PANOBINOSTAT; PONATINIB; PROTEIN BET; QUIZARTINIB; TEN 010; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CARCINOMA; DOWN REGULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; ENHANCER REGION; EPIGENETICS; GENE EXPRESSION REGULATION; HODGKIN DISEASE; HUMAN; IC50; LEUKEMIA; MAXIMUM TOLERATED DOSE; MLL GENE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR PROTEIN IN TESTIS MIDLINE CARCINOMA; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY SEQUENCE; REVIEW; RNA TRANSCRIPTION; SOLID TUMOR; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; LEUKEMIA; NEOPLASM PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84939194986     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.06.004     Document Type: Review

References (63)

1. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
2. Waddington C.H. The Epigenotype. 1942. Int J Epidemiol 2012, 41:10-13.
3. Dawson M.A., Kouzarides T., Huntly B.J.P. Targeting Epigenetic Readers in Cancer. N Engl J Med 2012, 367:647-657.
4. Turner B. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 2005, 12:110-112.
5. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
6. Filippakopoulos P., Knapp S. The bromodomain interaction module. FEBS Lett 2012, 586:2692-2704.
7. Wu S.Y., Chiang C.M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007, 282:13141-13145.
8. Maruyama T., Farina A., Dey A., et al. Mammalian bromodomain protein, brd4, interacts with replication factor c and inhibits progression to s phase. Mol Cell Biol 2002, 22:6509-6520.
9. Houzelstein D., Bullock S.L., Lynch D.E., Grigorieva E.F., Wilson V.A., Beddington R.S. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol Cell Biol 2002, 22:3794-3802.
10. Shang E., Wang X., Wen D., Greenberg D.A., Wolgemuth D.J. Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Dev Dyn 2009, 238:908-917.
11. Bolden J.E., Tasdemir N., Dow L.E., et al. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Rep 2014, 8:1919-1929.
12. Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399:491-496.
13. Rahman S., Sowa M.E., Ottinger M., et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011, 31:2641-2652.
14. You J., Srinivasan V., Denis G.V., et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein BRD4 on host mitotic chromosomes. J Virol 2006, 80:8909-8919.
15. Dawson M.A., Prinjha R.K., Dittmann A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Nature 2011, 478:529-533.
16. Jiang Y., Veschambre P., Erdjument-Bromage H., et al. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci U S A 1998, 95:8538-8543.
17. Sanchez R., Zhou M. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel 2009, 12:659-665.
18. Lovén J., Hoke H.A., Lin C.Y., et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. Cell 2009, 153:320-334.
19. Zhou Q., Li T., Price D.H. RNA polymerase II elongation control. Annu Rev Biochem 2012, 81:119-143.
20. Kwak H., Lis J.T. Control of transcriptional elongation. Annu Rev Genet 2013, 47:483-508.
21. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005, 19:523-534.
22. Schröder S., Cho S., Zeng L., et al. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem 2012, 287:1090-1099.
23. Wu S.Y., Lee A.Y., Lai H.T., Zhang H., Chiang C.M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene specific targeting. Mol Cell 2013, 49:843-857.
24. Huang B., Yang X.D., Zhou M.M., Ozato K., Chen L.F. Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA. Mol Cell Biol 2009, 29:1375-1387.
25. Ghosh S., May M., Kopp E. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
26. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
27. Lamonica J.M., Deng W., Kadauke S., et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci U S A 2011, 108:E159-E168.
28. Roe J.S., Mercan F., Rivera K., Pappin D.J., Vakoc C.R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol Cell 2015, 58:1028-1039.
29. Tessarz P., Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol 2014, 15:703-708.
30. LeRoy G., Rickards B., Flint S.J. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 2008, 30:51-60.
31. Kanno T., Kanno Y., LeRoy G., et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat Struct Mol Biol 2014, 21:1047-1057.
32. Zhang W., Prakash C., Sum C., et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem 2012, 287:43137-43155.
33. Whyte W.A., Orlando D.A., Hnisz D., et al. Master transcription factors and Mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
34. Andersson R., Gebhard C., Miguel-Escalada I., et al. An atlas of active enhancers across human cell types and tissues. Nature 2014, 507:455-461.
35. Liu W., Ma Q., Wong K., et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013, 155:1581-1595.
36. Mousavi K., Zare H., Dell'orso S., et al. eRNAs promote transcription by establishing chromatin accessibility at defined genomic loci. Mol Cell 2013, 51:606-617.
37. Smith E., Shilatifard A. Enhancer biology and enhanceropathies. Nat Struct Mol Biol 2014, 21:210-219.
38. Li W., Notani D., Ma Q., et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 2013, 498:516-520.
39. Lam M.T., Cho H., Lesch H.P., et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 2013, 498:511-515.
40. Hewings D.S., Rooney T.P., Jennings L.E., et al. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J Med Chem 2012, 55:9393-9413.
41. Filippakopoulos P., Qi J., Picaud S., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
42. Nicodeme E., Jeffrey K.L., Schaefer U., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
43. Delmore J.E., Issa G.C., Lemieux M.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
44. Mertz J.A., Conery A.R., Bryant B.M., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011, 108:16669-16674.
45. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukemia. Nature 2011, 478:524-528.
46. Mueller D., Garcia-Cuellar M.P., Bach C., et al. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 2009, 7:e1000249.
47. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
48. Lin C., Smith E.R., Takahashi H., et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010, 37:429-437.
49. Milne T.A., Kim J., Wang G.G., et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 2010, 38:853-863.
50. Muntean A.G., Tan J., Sitwala K., et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010, 17:609-621.
51. Dawson M.A., Gudgin E.J., Horton S.J., et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2013, 28:311-320.
52. Fiskus W., Sharma S., Qi J., et al. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT3-ITD. Mol Cancer Ther 2014, 13:2315-2327.
53. Stewart H.J., Horne G.A., Bastow S., Chevassut T.J. Brd4 associates with P53 in Dnmt3a-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor Jq1. Cancer Med 2013, 2:826-835.
54. Herrmann H., Blatt K., Shi J., et al. Small-molecule inhibition of Brd4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 2012, 3:1588-1599.
55. Ott C.J., Kopp N., Bird L., et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
56. Da Costa D., Agathanggelou A., Perry T., et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukemia. Blood Cancer J 2013, 3:e126.
57. Roderick J.E., Tesell J., Shultz L.D., et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014, 123:1040-1050.
58. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
59. Fiskus W., Sharma S., Qi J., et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014, 13:1142-1154.
60. Bhadury J., Nilsson L.M., Muralidharan S.V., et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A 2014, 111:E2721-E2730.
61. Moros A., Rodríguez V., Saborit-Villarroya I., et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia 2014, 28:2049-2059.
62. Siegel MB, Davare MA, Liu SQ, et al. The bromodomain inhibitor CPI203 demonstrates preclinical synergistic activity with bortezomib in drug resistant myeloma. Paper presented at: 56th ASH Annual Meeting and Exposition; December, 2014; San Francisco, CA, USA.
63. Dombret H, Preudhomme C, Berthon C, et al. (2014) A phase 1 study of the Bet-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. Paper presented at: 56th ASH Annual Meeting and Exposition; December, 2014; San Francisco, CA, USA.